Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01AZG
|
||||
Former ID |
DAP000003
|
||||
Drug Name |
Risperidone
|
||||
Synonyms |
Belivon; Risperdal; Risperdone; Risperidal; Risperidona; Risperidonum; Risperin; Rispolept; Rispolin; Sequinan; Risperdal Consta; Risperidona [Spanish]; Risperidonum [Latin]; R 62 766; R 64766; R64766; Consta, Risperdal; KS-1106; R 64,766; R-118; R-64766; R64,766; Risperdal (TN); Risperdal M-Tab; Risperidal M-Tab; Risperidone (RIS); Risperidone, placebo; R 64 766, Risperdal, Risperidone; R-64,766; R-64-766; Risperidone [USAN:BAN:INN]; Risperidone (JAN/USAN/INN); 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antipsychotic Agents
|
||||
Company |
Janssen-Cilag
|
||||
Structure |
Download2D MOL |
||||
Formula |
C23H27FN4O2
|
||||
InChI |
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
|
||||
InChIKey |
RAPZEAPATHNIPO-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 106266-06-2
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
631811, 7379882, 7847492, 7980523, 8153122, 11111724, 11111725, 11467057, 11468177, 11486814, 11528727, 12013967, 14904216, 17405630, 25819945, 26719830, 26753640, 29224142, 46386613, 46505850, 49658633, 49666400, 49681677, 49699257, 49830253, 50106974, 50106975, 50123965, 53778180, 53790689, 57322595, 80652519, 81092846, 85089206, 85170980, 85209258, 85231208, 85788353, 89736125, 92126063, 92303273, 92308377, 92308738, 92712792, 93166420, 93617025, 103170825, 103856459, 103914673, 103916252
|
||||
ChEBI ID |
ChEBI:8871
|
||||
SuperDrug ATC ID |
N05AX08
|
||||
SuperDrug CAS ID |
cas=106266062
|
||||
Target and Pathway | |||||
Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [536910], [537559] | |
References | |||||
Ref 536526 | Emerging anxiolytics. Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54. | ||||
Ref 543327 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 96). | ||||
Ref 536910 | Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269-92. | ||||
Ref 537559 | Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.